Drug intelligence / Profile preview

JRM-002

Development stage: Preclinical
Lead developer: Metcela
Modality: Stem Cell Therapies → Cell Therapies

Overview

JRM-002 is an autologous cardiac stem cell (CSC) therapy currently in preclinical development by Japan Regenerative Medicine, a subsidiary of Metcela. The therapy utilizes CSC technology licensed from Kyoto University to treat various forms of heart disease by promoting the regeneration of damaged cardiac tissue. Development is supported by manufacturing and clinical guidance from Okayama University. As of 2024, the program is in the early research or preclinical phase, following the company's lead candidate, JRM-001, which targets pediatric congenital heart disease.

Beyond the preview

Go deeper on JRM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRM-002.

Explore the full profile